Scavenger receptor class A (SR-A (also known as SCARA1 or MSR1 for the prototypical member))
Target
SR-A (also known as SCARA1 or MSR1 for the prototypical member)
Molecular classification
Receptor, Scavenger receptor superfamily (Class A subgroup), Type II membrane protein
01
Overview
Scavenger receptor class A is a family of cell-surface receptors predominantly found on macrophages and related myeloid cells. They bind and internalize a broad spectrum of ligands, including modified lipoproteins (like acetylated and oxidized LDL), bacterial surface molecules, amyloid-β, heat shock proteins, and apoptotic cells. SR-A receptors play essential roles in host defense, lipid metabolism, inflammation, and clearance of cellular debris. Structurally, they are type II membrane proteins featuring a collagen-like domain critical for ligand binding and commonly form homotrimers at the cell surface. SR-A1 is the best-characterized, and its activity is linked to foam cell formation in atherosclerosis, pathogen clearance via phagocytosis, and modulation of the innate immune response. Variants (SR-A1, 1.1, 3, 4, 5, 6, etc.) have differential expression and ligand specificity, contributing to tissue diversity and function
Ligand internalization and clearance (modified LDL, apoptotic cells, pathogens) Modulation of inflammation through interactions with toll-like receptors (TLRs) Alteration of lipid metabolism in macrophages (foam cell formation)
Cardiovascular disease (especially atherosclerosis, via foam cell formation)InflammationInfectious disease (clearance of bacteria and viruses)Neurodegenerative disease (Alzheimer’s—amyloid-β uptake)Autoimmune disease (e.g., SLE)Other (systemic, metabolic, immunologic contexts)
05
Safety considerations
Overactivation may promote foam cell formation and atherosclerosisPotential contribution to chronic inflammation, neurodegeneration, or autoimmunity via persistent ligand recognition and clearance functionsModulation may affect beneficial immune clearance of pathogens or apoptotic debris
06
Interacting drugs
There are currently no widely approved drugs that directly and specifically target scavenger receptor class A; research molecules exist, including antibodies and inhibitors used in animal models. Experimental modulation may occur via indirect means (statins, etc.), but no well-characterized therapeutic drugs specifically interact with SR-A in clinical use
07
Biomarkers
No standardized biomarkers for patient selection, but SR-A expression (especially SR-A1) in tissue macrophages or plasma may be explored as a candidate biomarker in research (for cardiovascular or inflammatory status)
Beyond the preview
Go deeper on Scavenger receptor class A (SR-A (also known as SCARA1 or MSR1 for the prototypical member)).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Drug pipeline
Explore the programs pursuing this target and their development progress.
Drug candidates
Developers
Development stage
Clinical trials
Follow the clinical studies evaluating therapies directed at this target.
Trial design
Status
Readouts
Competitive landscape
Compare approaches across drug candidates, modalities, and indications.
Programs
Modalities
Indications
Literature & evidence
Investigate the research and source evidence behind target biology and development.
Publications
Sources
Analysis
Patents
Explore patent activity around therapies and technologies addressing this target.
Patents
Assignees
Technologies
Research & analysis
Connect target biology, drug development, and emerging evidence in your research.
Biology
Development news
Analysis
Bring the full picture into focus.
See how Gosset can support your research on Scavenger receptor class A (SR-A (also known as SCARA1 or MSR1 for the prototypical member)).